We are Main Street
San Diego

ResMed Revenue Climbs 6% to $1.4 Billion in Q1

Operators should note rising demand for sleep devices and improved gross margins as the company launches new mask technology.

Updated on Oct. 29, 2026 in Corporate Finance

Isometric editorial illustration of a sterile medical valve and tubing, representing corporate growth in the sleep device sector.
ResMed reported a 6% revenue increase to $1.4 billion in the first quarter of fiscal 2027, driven by strong demand for sleep technology. AI Illustration. Upload story photo >

Live Poll

Do you prioritize companies with consistent dividend payments when deciding where to invest your money?

ResMed reported a 6% revenue increase to $1.4 billion for the first quarter of fiscal year 2027. The San Diego-based medical device maker also announced a quarterly cash dividend of $0.66 per share and the U.S. launch of its AirTouch F40 CPAP mask.

Why it matters

Growth in revenue and earnings reflects robust demand for sleep devices and masks, alongside operational improvements that increased gross margins. These results provide a benchmark for medical device operators navigating rising demand for respiratory equipment.

The company reported Q1 revenue of $1.4 billion, up 6% over the prior year, while GAAP diluted earnings per share rose 23% to $2.92. ResMed also achieved a non-GAAP gross margin of 62.5%, an increase of 50 basis points from the previous period.

The players

ResMed

A San Diego-based medical device company that develops and manufactures products for sleep-disordered breathing and respiratory conditions.

Carol Burt

A corporate governance professional who will serve as the Lead Director effective November 15, 2026.

The details

Profitability gains were fueled by strong sales volume across sleep devices and accessories, complemented by the completion of the MatrixCare business divestiture. The company also returned over $1.0 billion to shareholders through stock repurchases and dividends during the quarter. Going forward, the business projects non-GAAP diluted earnings per share between $12.00 and $12.25 for fiscal year 2027.

Timeline

  1. September 30, 2026: End of first fiscal quarter 2027.

  2. November 11, 2026: Ex-dividend date for common stockholders and CDI holders.

  3. November 12, 2026: Record date for quarterly cash dividend.

  4. November 15, 2026: Carol Burt appointment effective as Lead Director.

  5. December 17, 2026: Payment date for quarterly cash dividend.

Market Landscape

ResMed's performance reflects the ongoing industry trend of increased demand for home-based sleep and respiratory monitoring devices. The current quarterly figures align with the firm's fiscal 2027 growth targets for core constant currency revenue.

Operators in the medical equipment supply chain should monitor ResMed’s focus on gross margin expansion as a indicator of supply chain efficiency. Management’s projected earnings of $12.00 to $12.25 per share serves as a relevant market signal for capital allocation in the respiratory space.

The takeaway

Strong demand for sleep-related medical equipment continues to drive growth and shareholder value for industry leaders. Monitor the impact of new product launches like the AirTouch F40 mask on your own inventory turns and vendor partnerships throughout the fiscal year.

What happens next

The quarterly cash dividend of $0.66 per share is scheduled for payment on December 17, 2026.

Further reading

For more on the financial performance of health tech companies, visit Corporate Finance.

More information

View the complete results via the Resmed investor relations and earnings webcast.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you prioritize companies with consistent dividend payments when deciding where to invest your money?